The Search Is Narrowing. The Chair Is Still Open.

On May 6, 2026, Endpoints News reported that the FDA has narrowed its search for the next director of the Center for Biologics Evaluation and Research, but no name has been attached to the role. The reporting tracks ongoing speculation about who will lead a center that is, by submission volume, one of the busiest at the agency for the most regulatorily complex modalities currently in development.

For sponsors with active cell and gene therapy programs, the practical question is not who will eventually take the seat. It is how to manage submission timelines and review interactions during the interim period.

What Actually Changes During an Interim

In most regulatory teams, "interim leadership" gets translated to "things will be slower" and the planning ends there. That translation is roughly right, but it is too coarse to plan around. Three things actually change.

Decision velocity on novel matters slows. Decisions that involve substantive policy interpretation — particularly for first-in-class modalities, where the existing guidance leaves room for judgement — move more slowly during interim periods. Career staff are empowered to handle routine decisions, but novel matters tend to escalate, and the escalation chain has a missing link until the director is named. Sponsors with submissions that depend on a precedent-setting interpretation should expect their timelines to extend.

Major policy announcements pause. Interim directors do not, as a rule, announce significant new guidance or policy shifts. Existing guidance documents continue to be the operative reference. New guidance that was in draft when the seat opened tends to stay in draft. Sponsors that were waiting for a guidance document to clarify a regulatory question may need to plan around the existing ambiguity for longer than they expected.

Public-facing communications shift in tone. The center's public posture during an interim is more conservative. Press releases lean institutional. Conference presentations from senior CBER staff stick closer to existing positions. Sponsors trying to read the agency's direction from public signals get less signal during the interim than they got before.

What does not meaningfully change is the day-to-day review work. CBER's reviewers, project managers, and division directors continue to do their jobs. Information Requests still get sent. Filing reviews still happen. The submission you put in last quarter is still being read on schedule.

Tactical Adjustments for Active Filings

Three concrete adjustments are worth making during this period.

Front-load your engagement on novel matters. If your submission involves a question that needs precedent-setting interpretation — a novel manufacturing approach, a comparability question for an autologous product, a tissue source not yet seen at scale — request a Type B or Type C meeting now rather than later. The career staff who will handle the meeting are stable. The decision quality is high. The risk is that escalation to the director's office, if needed, becomes a longer wait once the seat is filled and the new director needs to come up to speed on the file.

Strengthen your briefing documents. During interim periods, well-constructed briefing documents that lay out the regulatory landscape, the relevant precedents, and the sponsor's proposed approach do more work than they do during stable periods. The reviewer is more reliant on the document because they have less ability to escalate ambiguity. A briefing document that anticipates questions and answers them in writing converts what would have been a stalled discussion into a faster decision.

Calibrate your timeline assumptions. If your submission's timeline assumes a major guidance update or a public position shift in the next two quarters, revisit the assumption. The probability of that shift is lower than it was before the seat opened. Build the alternative timeline that assumes existing guidance remains operative through the end of fiscal year 2026.

What This Says About Submission Quality

There is a broader read on this period that is worth holding onto.

When agency leadership is in transition, the quality of the submission matters more, not less. Marginal submissions that were going to require some judgement to clear can stall. High-quality submissions that present a clean regulatory case continue to move through the system.

Sponsors should treat interim periods as windows where the marginal investment in submission quality has higher returns than usual. That means more time spent on the briefing book. More time spent reconciling cross-references. More time spent making sure that the narrative across modules holds together. More time spent anticipating the questions a reviewer is most likely to ask under conservative interim guidance.

The teams that operate this way during interim periods come out the other side with cleaner regulatory histories. The teams that hope for the best and submit in the same shape they always have come out the other side with thicker Information Request stacks and longer cycles.

The Larger Pattern

This is not the first time CBER has been led by an interim, and it will not be the last. Center director transitions happen across the agency on roughly the cadence one would expect from any senior federal role — every few years, with periods of overlap and periods of vacancy.

The sponsors who plan for these transitions as a normal feature of the operating environment, rather than as a disruption to be reacted to, are the ones who build durable regulatory operations. They keep their briefing books current. They engage early and often. They calibrate their timelines against existing guidance, not anticipated guidance. They treat the agency's tooling, processes, and norms as the operative reality regardless of who is in the chair.

CBER will get a new director. The work in the meantime is the work it always was — and a little more careful than usual.